Skip to main content
Cathay Biotech Inc. logo

Cathay Biotech Inc. — Investor Relations & Filings

Ticker · 688065 ISIN · CNE100004447 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 753 across all filing types
Latest filing 2023-09-03 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688065

About Cathay Biotech Inc.

https://www.cathaybiotech.com/

Cathay Biotech Inc. specializes in the research, development, and commercial-scale production of bio-based materials through synthetic biology and metabolic engineering. The company’s core portfolio features long-chain diacids (LCDA), bio-based pentanediamine, and high-performance bio-based polyamides, including the Terryl and Ecopent product lines. These materials are utilized across various applications such as automotive components, electronics, consumer goods, and specialized textiles. By leveraging biological manufacturing processes to replace traditional thermochemical methods, the company provides sustainable alternatives to petroleum-derived chemicals. Cathay Biotech focuses on delivering high-performance, low-carbon solutions that support the transition toward a circular economy and reduced environmental impact in global supply chains.

Recent filings

Filing Released Lang Actions
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the board's approval of the share buyback scheme, the intended amount and price limits, and states that as of the date, no repurchase transactions have occurred yet. The document is short (918 characters) and focuses on the update of the share buyback activity rather than presenting financial statements or detailed financial data. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares.
2023-09-03 Chinese
中信证券股份有限公司关于上海凯赛生物技术股份有限公司使用部分超募资金回购股份的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the use of excess raised funds by Shanghai Kaisa Biotechnology Co., Ltd. to repurchase shares. It includes extensive information about the fundraising, investment projects, the purpose and method of the share repurchase, the amount and price limits, the impact on the company, legal compliance, and the approval process. The document is lengthy (9130 characters) and contains substantive financial and operational details related to the share repurchase plan. It is not merely an announcement or a brief summary but a comprehensive verification opinion and analysis related to a capital/financing activity (share repurchase using excess funds). Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2023-08-30 Chinese
招商证券股份有限公司关于上海凯赛生物技术股份有限公司使用部分超募资金回购股份的核查意见
Transaction in Own Shares Classification · 95% confidence The document is a detailed report from a securities company (招商证券股份有限公司) acting as a sponsor and auditor for Shanghai Kaisai Biotechnology Co., Ltd. It focuses on the company's use of part of its over-raised funds to repurchase shares. The document includes extensive details on the purpose, method, amount, price, and impact of the share repurchase, as well as compliance with relevant laws and regulations. It also contains the sponsor's verification opinion and independent directors' opinions on the share repurchase plan. The document is lengthy (8756 characters) and contains substantive financial and procedural information about the share repurchase, not just an announcement or a brief summary. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares. It is not a simple announcement or a regulatory filing, but a comprehensive disclosure about the share repurchase plan and its details.
2023-08-30 Chinese
关于以集中竞价交易方式回购股份的回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Shanghai Kaisai Biotechnology Co., Ltd. regarding a share repurchase plan. It includes specifics about the purpose, scale, price, funding source, authorization, risks, and procedures of the share buyback. The text repeatedly mentions the company's plan to repurchase shares through centralized bidding, the intended use of repurchased shares for employee stock ownership plans or equity incentives, and the regulatory compliance of the buyback. There is no indication that this is a financial report, earnings release, or management discussion. Instead, it is a comprehensive report on the company's share repurchase activity, which fits the definition of a Transaction in Own Shares (POS) filing. The document length and detail confirm it is the report itself, not just an announcement of a report publication or a regulatory filing. Therefore, the correct classification is POS with high confidence.
2023-08-30 Chinese
中信证券股份有限公司关于上海凯赛生物技术股份有限公司2023年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023 Half-Year Continuous Supervision Tracking Report" issued by CITIC Securities for Shanghai Kaisa Biotechnology Co., Ltd. It details the ongoing supervision activities, risk factors, financial data for the first half of 2023, and compliance with regulatory requirements. The content includes detailed financial figures for the half-year period (January to June 2023), risk disclosures, operational updates, and governance oversight. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year. It is not an announcement or a brief summary but a detailed report covering the half-year performance and supervision. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-30 Chinese
招商证券股份有限公司关于上海凯赛生物技术股份有限公司2023年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 Semi-Annual Continuous Supervision Tracking Report' issued by the sponsor institution (招商证券股份有限公司) for Shanghai Kaisai Biotechnology Co., Ltd. It details the continuous supervision work, risk factors, financial data for the first half of 2023, and compliance with regulations. The content includes detailed financial figures, risk analysis, governance and compliance information, and operational updates for a half-year period. This matches the characteristics of an Interim / Quarterly Report (IR), as it provides a comprehensive financial report for a period shorter than a full fiscal year with substantive financial data and analysis. The document is not a brief announcement or a certification letter, nor is it a full annual report or other specific filing type. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-08-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.